Wegovy is the trade name of a prescription medicine containing semaglutide. It is used for long-term weight management in certain people with obesity or weight-related conditions, always alongside diet, physical activity and medical supervision.
Treatment can substantially reduce weight, but is neither a quick cosmetic solution nor suitable for everyone. Benefits, side effects, costs and the often necessary longer-term use should be weighed up with a doctor before starting.
How Wegovy works
Semaglutide resembles the body’s intestinal hormone GLP-1. It affects satiety and appetite and temporarily slows stomach emptying. This makes it easier for many people receiving treatment to consume less energy. However, the medicine does not independently burn fat or replace sustainable everyday habits.
- Use follows the doctor’s dosing plan.
- Benefit varies between individuals.
- Weight may increase again after stopping.
Who the treatment is intended for
European authorisation ties use to body mass index, associated conditions and age. It is also authorised for certain adolescents under defined conditions. Its suitability in an individual case also depends on pre-existing conditions, other medicines and previous treatment attempts.
- Wegovy must not be used during pregnancy or breastfeeding. Before a planned pregnancy, semaglutide must be stopped at least 2 months beforehand with medical supervision.
- Before surgery or anaesthesia, the treatment team must be informed about semaglutide.
- Do not combine it with other GLP-1 medicines on your own initiative.
Assessing effectiveness realistically
In large studies, participants receiving semaglutide lost more weight on average than those receiving placebo. However, averages do not predict an individual’s response. Some achieve much less weight loss, while others stop because of side effects. Blood pressure, blood glucose, muscle mass and quality of life are important measures of progress alongside the number on the scales.
Side effects and warning signs
Nausea, diarrhoea, constipation, vomiting and abdominal pain are common, particularly during dose escalation. Gallbladder and pancreas risks are also important, as is dehydration with severe vomiting or diarrhoea. Sudden, severe and persistent abdominal pain or marked dehydration require prompt medical assessment. Seek immediate medical help for severe allergic reactions. The very rare optic nerve condition NAION is also described; seek immediate ophthalmological help for sudden loss of vision.
Conclusion
With an appropriate indication, Wegovy can be an effective component of obesity treatment. Realistic expectations, a plan for diet and physical activity, and regular monitoring of effects and tolerability are essential.
Related articles
Source framework
EMA product information for Wegovy; German obesity guideline; BfArM. Sources and recommendations may change; current professional information and personal advice apply to medical decisions.
Note: This article provides general health information. It does not replace examination, diagnosis or treatment by qualified medical professionals.
